Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics N.V. reports developments as a clinical-stage biopharmaceutical company built around its proprietary Axiomer™ RNA editing platform. The technology uses ADAR-mediated RNA editing to make single-nucleotide changes in RNA, with pipeline updates centered on AX-0810 and additional programs across rare and prevalent diseases with unmet need.
Recurring company news includes scientific conference presentations, investor and analyst events, clinical-program updates, development-candidate selections, AI-enabled discovery initiatives, and collaborations such as Ginkgo Bioworks and Eli Lilly. ProQR also reports annual operating and financial results, annual general meeting materials, board composition changes, and other governance matters tied to its Nasdaq-listed public-company profile.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced key presentations at upcoming conferences to showcase its Axiomer® RNA editing platform. Events include the Oligonucleotide and Precision Therapeutics (OPT) Congress on March 14, 2023, where CSO Gerard Platenburg will discuss therapeutic potentials of Editing Oligonucleotides (EONs). Additionally, at the RNA Leaders Europe Congress on March 16, 2023, CEO Daniel A. de Boer will explore the transformative capabilities of Axiomer. The RNA Editing Gordon Research Conference on March 23, 2023, will feature Platenburg's insights into addressing liver disorders with Axiomer. This innovative platform aims to revolutionize RNA therapies for various unmet medical needs.
ProQR Therapeutics N.V. (Nasdaq: PRQR) will host a virtual R&D event on March 29, 2023, from 10:00 am to 12:30 pm EDT. The event will feature the Company’s Axiomer® RNA-editing technology and outline initial pipeline targets for development. Key speakers include CEO Daniel A. de Boer and Chief Scientific Officer Gerard Platenburg. The Company will also release its full year 2022 operating and financial results on the same date. Registration for the event is available on ProQR's website, and an archived webcast will be accessible for 30 days post-event. This initiative underscores ProQR's commitment to advancing RNA therapies aimed at treating diverse diseases.
ProQR Therapeutics N.V. (Nasdaq: PRQR) has announced an investor conference call and webcast on December 22, 2022, at 8:15am EST to discuss its Axiomer RNA editing technology, following an expanded partnership with Eli Lilly. The Axiomer platform utilizes the body's own ADAR machinery to edit RNA, potentially leading to new treatments for various diseases. The call will be accessible live and archived for 30 days. ProQR aims to develop transformative RNA therapies that address significant unmet medical needs.
ProQR Therapeutics and Eli Lilly expand their collaboration to develop genetic medicines using Axiomer technology. The updated agreement, initially forged in September 2021, aims to enhance RNA editing for liver and nervous system disorders. ProQR will receive $75 million in upfront payment and equity, with potential total earnings of $3.75 billion in milestones and royalties. The collaboration signifies a strong commitment to addressing high unmet medical needs.
Eli Lilly and ProQR Therapeutics announced an expanded collaboration on December 22, 2022, focusing on genetic medicines utilizing ProQR's Axiomer RNA editing technology. The partnership, originally established in September 2021, will now target additional disorders affecting the central and peripheral nervous systems. ProQR will receive $75 million upfront and an option for an additional $50 million. The total potential value of the collaboration is approximately $3.75 billion in milestones and royalties. This collaboration aims to develop innovative treatments for diseases with significant unmet needs.
On November 14, 2022, ProQR Therapeutics N.V. (Nasdaq: PRQR) announced their upcoming presentation at the TIDES Europe conference, scheduled for November 16-18, 2022, in Vienna, Austria. The oral presentation, titled Progress on Development of RNA Base Editing Technologies for Precision Medicines, will be delivered by Co-Founder and Chief Scientific Officer Gerard Platenburg on November 18, 2022, at 2:30 PM CET. ProQR is pioneering Axiomer® technology to create transformative RNA therapies aimed at correcting disease-causing mutations.
ProQR Therapeutics (Nasdaq: PRQR) reported its Q3 2022 results, focusing on its Axiomer RNA base editing technology for treating genetic disorders. The company continues its partnership with Eli Lilly and plans to unveil initial pipeline targets in early 2023. Financially, ProQR's cash decreased to €100.4 million, with a net loss of €24.4 million (or €0.34 per share). Operating expenses rose, with R&D costs at €15.4 million. Positive developments include the appointment of key management members and a cash runway extending into 2026.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its participation in the Stifel 2022 Healthcare Conference. The Company's fireside chat is scheduled for November 16, 2022, from 10:20 to 10:50 am EST, with a replay available for 30 days. ProQR specializes in RNA therapies and is pioneering Axiomer®, a technology for making precise RNA edits to treat genetic diseases. The Company emphasizes its commitment to developing transformative therapies aimed at improving patients' lives.
ProQR Therapeutics N.V. (Nasdaq: PRQR) has announced a strategic shift focusing on its Axiomer® RNA editing technology after receiving guidance from the European Medicines Agency (EMA) regarding sepofarsen. An additional pivotal trial for sepofarsen is now required prior to a Marketing Authorisation Application. The company will seek a strategic partner for its ophthalmology assets while winding down current trials, which will lead to workforce reductions but extend its cash runway into 2026.
ProQR Therapeutics has accelerated its Axiomer® RNA base-editing technology and plans to update on initial targets in H2 2022. The company is in discussions with the EMA and FDA regarding data from the Illuminate trial and the regulatory path for ultevursen. Ongoing enrollment in the Sirius Phase 2/3 trial for USH2A-mediated Usher syndrome continues. Financially, ProQR reported €156.4 million in cash as of June 30, 2022, with a net loss of €14.7 million for the quarter. R&D expenses increased to €11.4 million compared to last year.